{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:19Z","timestamp":1793747059953,"version":"4.6.1"},"reference-count":132,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T00:00:00Z","timestamp":1530316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["FMM-AP16683-2017"],"award-info":[{"award-number":["FMM-AP16683-2017"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010188","name":"Consejo de Ciencia y Tecnolog\u00eda del Estado de Chiapas","doi-asserted-by":"publisher","award":["PI-0089-2017"],"award-info":[{"award-number":["PI-0089-2017"]}],"id":[{"id":"10.13039\/501100010188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ovarian cancer is the most lethal gynecological malignancy in developed countries. This is due to the lack of specific symptoms that hinder early diagnosis and to the high relapse rate after treatment with radical surgery and chemotherapy. Hence, novel therapeutic modalities to improve clinical outcomes in ovarian malignancy are needed. Progress in gene therapy has allowed the development of several strategies against ovarian cancer. Most are focused on the design of improved vectors to enhance gene delivery on the one hand, and, on the other hand, on the development of new therapeutic tools based on the restoration or destruction of a deregulated gene, the use of suicide genes, genetic immunopotentiation, the inhibition of tumour angiogenesis, the alteration of pharmacological resistance, and oncolytic virotherapy. In the present manuscript, we review the recent advances made in gene therapy for ovarian cancer, highlighting the latest clinical trials experience, the current challenges and future perspectives.<\/jats:p>","DOI":"10.3390\/ijms19071930","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T10:56:52Z","timestamp":1530529012000},"page":"1930","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Recent Progress in Gene Therapy for Ovarian Cancer"],"prefix":"10.3390","volume":"19","author":[{"given":"\u00c1ngela","family":"\u00c1yen","sequence":"first","affiliation":[{"name":"Department of Human Anatomy and Embryology, University of Granada, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Jim\u00e9nez Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Biopathology and Medicine Regenerative Institute (IBIMER), University of Granada, 18016 Granada, Spain"},{"name":"Biosanitary Institute of Granada (ibs.GRANADA), SAS-Universidad de Granada, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4996-8261","authenticated-orcid":false,"given":"Juan A.","family":"Marchal","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy and Embryology, University of Granada, 18016 Granada, Spain"},{"name":"Biopathology and Medicine Regenerative Institute (IBIMER), University of Granada, 18016 Granada, Spain"},{"name":"Biosanitary Institute of Granada (ibs.GRANADA), SAS-Universidad de Granada, 18016 Granada, Spain"},{"name":"Excellence Research Unit \u201cModeling Nature\u201d (MNat), University of Granada, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4433-7556","authenticated-orcid":false,"given":"Houria","family":"Boulaiz","sequence":"additional","affiliation":[{"name":"Department of Human Anatomy and Embryology, University of Granada, 18016 Granada, Spain"},{"name":"Biopathology and Medicine Regenerative Institute (IBIMER), University of Granada, 18016 Granada, Spain"},{"name":"Biosanitary Institute of Granada (ibs.GRANADA), SAS-Universidad de Granada, 18016 Granada, Spain"},{"name":"Excellence Research Unit \u201cModeling Nature\u201d (MNat), University of Granada, 18016 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Papp","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.ijgo.2015.06.007","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"131","author":"Berek","year":"2015","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PGP.0000000000000342","article-title":"Value of Pathology Review in a Population-based Series of Ovarian Tumors","volume":"36","author":"Stewart","year":"2017","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GRF.0b013e31824b4611","article-title":"Ovarian cancer: Etiology, risk factors, and epidemiology","volume":"55","author":"Hunn","year":"2012","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force, Grossman, D.C., Curry, S.J., Owens, D.K., Barry, M.J., Davidson, K.W., Doubeni, C.A., Epling, J.W., Kemper, A.R., and Krist, A.H. (2018). Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 319, 588\u2013594.","DOI":"10.1001\/jama.2017.21926"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2018.03.050","article-title":"A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma","volume":"149","author":"Han","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nrg2971","article-title":"State-of-the-art gene-based therapies: The road ahead","volume":"12","author":"Kay","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.nucmedbio.2013.10.005","article-title":"Biodistribution and antitumor effect of Cetuximab-targeted lentivirus","volume":"41","author":"Huhtala","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"ref_13","first-page":"120","article-title":"Adenoviral-delivered HE4-HSV-tk sensitizes ovarian cancer cells to ganciclovir","volume":"15","author":"Rawlinson","year":"2013","journal-title":"Gene Ther. Mol. Biol."},{"key":"ref_14","first-page":"733","article-title":"Preparation of a novel adenovirus formulation with artificial envelope of multilayer polymer-coatings: Therapeutic effect on metastatic ovarian cancer","volume":"23","author":"Yoshihara","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2014.07.105","article-title":"AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer","volume":"135","author":"Xie","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/gt.2010.15","article-title":"Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer","volume":"17","author":"Nguyen","year":"2010","journal-title":"Gene Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/cgt.2009.47","article-title":"Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin","volume":"17","author":"Yang","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"ref_18","first-page":"E4418","article-title":"AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer","volume":"112","author":"Sosulski","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hung, C.-F., Chiang, A.J., Tsai, H.-H., Pomper, M.G., Kang, T.H., Roden, R.R., and Wu, T.-C. (2012). Ovarian cancer gene therapy using HPV-16 pseudovirion carrying the HSV-tk gene. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040983"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kang, Y., Zhang, X., Jiang, W., Wu, C., Chen, C., Zheng, Y., Gu, J., and Xu, C. (2009). Tumor-directed gene therapy in mice using a composite nonviral gene delivery system consisting of the piggyBac transposon and polyethylenimine. BMC Cancer, 9.","DOI":"10.1186\/1471-2407-9-126"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/03639045.2010.489563","article-title":"Nonviral gene delivery to human ovarian cancer cells using arginine-grafted PAMAM dendrimer","volume":"37","author":"Jang","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/IJN.S93496","article-title":"Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene","volume":"11","author":"Luo","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"76432","DOI":"10.18632\/oncotarget.19464","article-title":"Enhanced antitumor effect of biodegradable cationic heparin-polyethyleneimine nanogels delivering FILIP1L\u0394C103 gene combined with low-dose cisplatin on ovarian cancer","volume":"8","author":"Xie","year":"2017","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7150\/ijms.10929","article-title":"Efficient Inhibition of Ovarian Cancer by Gelonin Toxin Gene Delivered by Biodegradable Cationic Heparin-polyethyleneimine Nanogels","volume":"12","author":"Bai","year":"2015","journal-title":"Int. J. Med. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejps.2013.10.011","article-title":"Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: For the potential targeted ovarian cancer gene therapy","volume":"52","author":"Li","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1021\/mp4006672","article-title":"Multifunctional disulfide-based cationic dextran conjugates for intravenous gene delivery targeting ovarian cancer cells","volume":"11","author":"Song","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.2147\/IJN.S115367","article-title":"Efficient delivery of Notch1 siRNA to SKOV3 cells by cationic cholesterol derivative-based liposome","volume":"11","author":"Zhao","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"39152","DOI":"10.1021\/acsami.7b10796","article-title":"Ovarian Cancer Therapy by VSVMP Gene Mediated by a Paclitaxel-Enhanced Nanoparticle","volume":"9","author":"Long","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.03.025","article-title":"Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment","volume":"183","author":"Florinas","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ultsonch.2012.06.015","article-title":"Targeted microbubbles for ultrasound mediated gene transfection and apoptosis induction in ovarian cancer cells","volume":"20","author":"Chang","year":"2013","journal-title":"Ultrason. Sonochem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1021\/mp500835z","article-title":"Targeted Microbubbles for Ultrasound Mediated Short Hairpin RNA Plasmid Transfection to Inhibit Survivin Gene Expression and Induce Apoptosis of Ovarian Cancer A2780\/DDP Cells","volume":"12","author":"Zhang","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2017.77.0446","article-title":"Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology","volume":"36","author":"Heymach","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_33","first-page":"880","article-title":"The Promise of Chimeric Antigen Receptor T-Cell Therapy","volume":"30","author":"Frey","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"64607","DOI":"10.18632\/oncotarget.19929","article-title":"CAR-T cell therapy in ovarian cancer: From the bench to the bedside","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/imt-2017-0039","article-title":"Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy","volume":"9","author":"Zhang","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/stem.645","article-title":"Concise review: Mesenchymal stem cell tumor-homing: Detection methods in disease model systems","volume":"29","author":"Reagan","year":"2011","journal-title":"Stem Cells"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1757-2215-7-8","article-title":"Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice","volume":"7","author":"Zhang","year":"2014","journal-title":"J. Ovarian Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00432-009-0728-8","article-title":"The effect of endostatin mediated by human mesenchymal stem cells on ovarian cancer cells in vitro","volume":"136","author":"Jiang","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcyt.2012.10.003","article-title":"Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer","volume":"15","author":"Dembinski","year":"2013","journal-title":"Cytotherapy"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1757-2215-3-12","article-title":"Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor","volume":"3","author":"Komarova","year":"2010","journal-title":"J. Ovarian Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1021\/acs.nanolett.5b04237","article-title":"Nanoghosts as a Novel Natural Nonviral Gene Delivery Platform Safely Targeting Multiple Cancers","volume":"16","author":"Kaneti","year":"2016","journal-title":"Nano Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.canlet.2017.11.025","article-title":"The future of mesenchymal stem cell-based therapeutic approaches for cancer\u2014From cells to ghosts","volume":"414","author":"Mohr","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_43","first-page":"152","article-title":"Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer","volume":"4","author":"Malecki","year":"2013","journal-title":"J. Genet. Syndr. Gene Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1158\/1535-7163.MCT-09-0056","article-title":"A novel hTERT promoter-driven E1A therapeutic for ovarian cancer","volume":"8","author":"Xie","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kim, Y.-C., Kim, B.-G., and Lee, J.-H. (2012). Thymosin \u03b210 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035399"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.1158\/0008-5472.CAN-09-0061","article-title":"Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice","volume":"69","author":"Huang","year":"2009","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1158\/1535-7163.MCT-16-0501","article-title":"Dual-Targeting Nanoparticles for in Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells","volume":"16","author":"Cocco","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"23764","DOI":"10.1038\/srep23764","article-title":"Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex","volume":"6","author":"He","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jconrel.2013.10.015","article-title":"Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts","volume":"172","author":"He","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/fon.12.171","article-title":"Intraperitoneal delivery of nanoparticles for cancer gene therapy","volume":"9","author":"Dass","year":"2013","journal-title":"Future Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1447-0756.2006.00435.x","article-title":"In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice","volume":"32","author":"Collinet","year":"2006","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/gyno.2001.6488","article-title":"Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells","volume":"84","author":"Kigawa","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.cgt.7700727","article-title":"Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status","volume":"11","author":"Quist","year":"2004","journal-title":"Cancer Gene Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/CAD.0b013e32832dad3d","article-title":"Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy","volume":"20","author":"Miettinen","year":"2009","journal-title":"Anticancer Drugs"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3892\/mmr.2014.2784","article-title":"Biological characteristics of Taxol-resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53","volume":"11","author":"Liu","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(03)01139-2","article-title":"Why did p53 gene therapy fail in ovarian cancer?","volume":"4","author":"Zeimet","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000158664","article-title":"Efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene, hPNAS-4, in a mouse model. In vivo and in vitro results","volume":"75","author":"Yang","year":"2008","journal-title":"Oncology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canlet.2008.06.018","article-title":"Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene","volume":"271","author":"Wu","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1242\/jcs.137521","article-title":"Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction","volume":"126","author":"Lee","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_61","first-page":"3233","article-title":"Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells in vitro and in vivo","volume":"15","author":"Lu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11596-010-0358-z","article-title":"Cloning of WWOX gene and its growth-inhibiting effects on ovarian cancer cells","volume":"30","author":"Xiong","year":"2010","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3892\/mmr.2015.3640","article-title":"Effect of the WWOX gene on the regulation of the cell cycle and apoptosis in human ovarian cancer stem cells","volume":"12","author":"Yan","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Dickerson, E.B., Blackburn, W.H., Smith, M.H., Kapa, L.B., Lyon, L.A., and McDonald, J.F. (2010). Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-10"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12032-010-9808-5","article-title":"RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells","volume":"29","author":"Lin","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1756-9966-30-83","article-title":"Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells","volume":"30","author":"Zhang","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11596-013-1109-8","article-title":"Effect of siRNA targeting MTA1 on metastasis malignant phenotype of ovarian cancer A2780 cells","volume":"33","author":"Rao","year":"2013","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3892\/mmr.2014.2131","article-title":"Silencing of cyclooxygenase-2 inhibits the growth, invasion and migration of ovarian cancer cells","volume":"9","author":"Lin","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3892\/mmr.2014.2732","article-title":"Effects of cyclooxygenase-2 gene silencing on the biological behavior of SKOV3 ovarian cancer cells","volume":"11","author":"Guo","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_70","first-page":"651","article-title":"Effect of WT1 antisense mRNA on the induction of apoptosis in ovarian carcinoma SKOV3 cells","volume":"32","author":"Huo","year":"2011","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1447-0756.2012.02007.x","article-title":"Efficient inhibition of intraperitoneal ovarian cancer growth in nude mice by liposomal delivery of short hairpin RNA against STAT3","volume":"39","author":"Jiang","year":"2013","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1073\/pnas.0813348106","article-title":"Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis","volume":"106","author":"Huang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","first-page":"193","article-title":"Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3","volume":"26","author":"Sun","year":"2011","journal-title":"Oncol. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/cmi.2009.8","article-title":"CD59 silencing via retrovirus-mediated RNA interference enhanced complement-mediated cell damage in ovary cancer","volume":"6","author":"Shi","year":"2009","journal-title":"Cell. Mol. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hum.2017.209","article-title":"In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9","volume":"29","author":"He","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/13543776.2016.1211640","article-title":"Cancer suicide gene therapy: A patent review","volume":"26","author":"Navarro","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.lfs.2013.08.015","article-title":"A novel plasmid and SonoVue formulation plus ultrasound sonication for effective gene delivery in nude mice","volume":"93","author":"Wang","year":"2013","journal-title":"Life Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3892\/etm.2014.1877","article-title":"Inhibitory effects of the ultrasound-targeted microbubble destruction-mediated herpes simplex virus-thymidine kinase\/ganciclovir system on ovarian cancer in mice","volume":"8","author":"Zhou","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/onc.2012.134","article-title":"Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth","volume":"32","author":"Sher","year":"2013","journal-title":"Oncogene"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.gt.3303081","article-title":"Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo","volume":"15","author":"White","year":"2008","journal-title":"Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Singh, P.P., Joshi, S., Russell, P.J., Nair, S., and Khatri, A. (2011). Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer. BMC Cancer, 11.","DOI":"10.1186\/1471-2407-11-368"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/cgt.2015.61","article-title":"Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models","volume":"23","author":"Kobayashi","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.22307","article-title":"Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1\/Flt-1 using adeno-associated virus serotype 1-derived vector","volume":"120","author":"Takei","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1158\/1078-0432.CCR-05-0910","article-title":"Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model","volume":"11","author":"Hu","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/mt.2008.258","article-title":"Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice","volume":"17","author":"Sallinen","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/ijc.27495","article-title":"Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma","volume":"131","author":"Sopo","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/humc.2013.006","article-title":"Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer","volume":"24","author":"Tuppurainen","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/IGC.0000000000000973","article-title":"Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice","volume":"27","author":"Tuppurainen","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1089\/104303401750476221","article-title":"Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites","volume":"12","author":"Hampl","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.gt.3302352","article-title":"Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice","volume":"12","author":"Subramanian","year":"2005","journal-title":"Gene Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.imbio.2008.11.002","article-title":"Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model","volume":"214","author":"Dou","year":"2009","journal-title":"Immunobiology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3727\/096368910X536509","article-title":"Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice","volume":"20","author":"Hu","year":"2011","journal-title":"Cell Transplant."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jgm.1356","article-title":"Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally","volume":"11","author":"Fewell","year":"2009","journal-title":"J. Gene Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/vim.2008.0029","article-title":"rAAV\/Her-2\/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer","volume":"21","author":"Yu","year":"2008","journal-title":"Viral Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.canlet.2013.10.011","article-title":"Murine double minute 2 siRNA and wild-type p53 gene therapy enhances sensitivity of the SKOV3\/DDP ovarian cancer cell line to cisplatin chemotherapy in vitro and in vivo","volume":"343","author":"Gu","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s11095-014-1602-1","article-title":"Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer","volume":"32","author":"Yang","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/nnm.11.131","article-title":"Two-in-one: Combined targeted chemo and gene therapy for tumor suppression and prevention of metastases","volume":"7","author":"Zhang","year":"2012","journal-title":"Nanomedicine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-011-1135-5","article-title":"Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer","volume":"138","author":"Rein","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-11-0233","article-title":"Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer","volume":"17","author":"Han","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3892\/mmr.2012.1216","article-title":"Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells","volume":"7","author":"Jiang","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1158\/1535-7163.MCT-14-0556","article-title":"Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer","volume":"14","author":"Salzano","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"7821","DOI":"10.1021\/acsami.7b19183","article-title":"Enhanced Chemotherapeutic Efficacy of Paclitaxel Nanoparticles Co-delivered with MicroRNA-7 by Inhibiting Paclitaxel-Induced EGFR\/ERK pathway Activation for Ovarian Cancer Therapy","volume":"10","author":"Cui","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_103","first-page":"139","article-title":"Circadian Gene CLOCK Affects Drug-Resistant Gene Expression and Cell Proliferation in Ovarian Cancer SKOV3\/DDP Cell Lines Through Autophagy","volume":"32","author":"Sun","year":"2017","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.7314\/APJCP.2015.16.8.3517","article-title":"Involvement of GRP78 in the Resistance of Ovarian Carcinoma Cells to Paclitaxel","volume":"16","author":"Zhang","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3892\/ol.2012.926","article-title":"In vitro and in vivo growth inhibition of drug-resistant ovarian carcinoma cells using a combination of cisplatin and a TRAIL-encoding retrovirus","volume":"4","author":"Li","year":"2012","journal-title":"Oncol. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"16003","DOI":"10.1038\/mto.2016.3","article-title":"Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2\/neu or EpCAM as target receptors","volume":"3","author":"Hanauer","year":"2016","journal-title":"Mol. Ther. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ijc.28450","article-title":"Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites","volume":"134","author":"Jennings","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13048-016-0282-3","article-title":"IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice","volume":"9","author":"Thomas","year":"2016","journal-title":"J. Ovarian Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/ijc.28631","article-title":"Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer","volume":"134","author":"Goshima","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1038\/mto.2016.21","article-title":"Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy","volume":"3","author":"Dold","year":"2016","journal-title":"Mol. Ther. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omto.2017.08.002","article-title":"Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model","volume":"6","author":"Nounamo","year":"2017","journal-title":"Mol. Ther. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.2147\/OTT.S113014","article-title":"Synergistic suppression effect on tumor growth of ovarian cancer by combining cisplatin with a manganese superoxide dismutase-armed oncolytic adenovirus","volume":"9","author":"Wang","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2013.05.004","article-title":"Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase","volume":"130","author":"Hartkopf","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_114","unstructured":"(2018, June 29). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/gt.2009.159","article-title":"Phase-I clinical trial of IL-12 plasmid\/lipopolymer complexes for the treatment of recurrent ovarian cancer","volume":"17","author":"Anwer","year":"2010","journal-title":"Gene Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ygyno.2013.07.081","article-title":"Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer","volume":"131","author":"Anwer","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","article-title":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A gynecologic oncology group study","volume":"133","author":"Alvarez","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2017.08.001","article-title":"A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal","volume":"147","author":"Thaker","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-11-2852","article-title":"A phase I clinical trial of Ad5.SSTR\/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer","volume":"18","author":"Kim","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ygyno.2013.06.003","article-title":"A phase I clinical trial of Ad5\/3-\u039424, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer","volume":"130","author":"Kim","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1158\/1078-0432.CCR-10-0791","article-title":"A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases","volume":"16","author":"Kimball","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1017\/S1478951515000127","article-title":"A systematic review of ovarian cancer and fear of recurrence","volume":"13","author":"Ozga","year":"2015","journal-title":"Palliat. Support. Care"},{"key":"ref_124","first-page":"48","article-title":"Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance","volume":"22","author":"Klemba","year":"2018","journal-title":"Contemp. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-017-0638-3","article-title":"Ovarian cancer stem cells: Still an elusive entity?","volume":"16","author":"Lupia","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"12503","DOI":"10.18632\/oncotarget.23605","article-title":"Could ALDH2*2 be the reason for low incidence and mortality of ovarian cancer for East Asia women?","volume":"9","author":"Yan","year":"2018","journal-title":"Oncotarget"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Testa, U., Petrucci, E., Pasquini, L., Castelli, G., and Pelosi, E. (2018). Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medcine, 5.","DOI":"10.3390\/medicines5010016"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejmech.2017.06.030","article-title":"Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer","volume":"142","author":"Markowska","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.2147\/OTT.S155458","article-title":"Are ovarian cancer stem cells the target for innovative immunotherapy?","volume":"11","author":"Wang","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3892\/or.2016.5263","article-title":"Adenovirus-mediated truncated Bid overexpression induced by the Cre\/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells","volume":"37","author":"Long","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13048-018-0403-2","article-title":"Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: Studies based on the CRISPR\/Cas9 system","volume":"11","author":"Ling","year":"2018","journal-title":"J. Ovarian Res."},{"key":"ref_132","first-page":"604","article-title":"The significance of the pluripotency and cancer stem cell-related marker NANOG in diagnosis and treatment of ovarian carcinoma","volume":"37","author":"Smrkolj","year":"2016","journal-title":"Eur. J. Gynaecol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/7\/1930\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:10:50Z","timestamp":1760195450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/7\/1930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,30]]},"references-count":132,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"alternative-id":["ijms19071930"],"URL":"https:\/\/doi.org\/10.3390\/ijms19071930","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,30]]}}}